Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial

医学 肺结核 不利影响 间充质干细胞 骨髓 痰 内科学 结核分枝杆菌 免疫学 外科 病理
作者
Aliaksandr Skrahin,Raija Ahmed,Giovanni Ferrara,Lalit Rane,Thomas Poiret,Yanina Isaikina,Alena Skrahina,Alimuddin Zumla,Markus Maeurer
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:2 (2): 108-122 被引量:138
标识
DOI:10.1016/s2213-2600(13)70234-0
摘要

Background Novel treatment options are urgently needed for multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis, which are associated with immune dysfunction and poor treatment outcomes. Mesenchymal stromal cells (MSCs) are immunomodulatory and adjunct autologous treatment with bone marrow-derived MSCs might improve clinical outcome by transforming chronic inflammation into productive immune responses. Our aim was to assess the safety of infusion of autologous MSCs as an adjunct treatment in patients with tuberculosis. Methods 30 patients with microbiologically confirmed MDR or XDR tuberculosis were treated with single-dose autologous bone marrow-derived MSCs (aimed for 1×106 cells per kg), within 4 weeks of the start of antituberculosis-drug treatment in a specialist centre in Minsk, Belarus. Inclusion patients were those with pulmonary tuberculosis confirmed by sputum smear microscopy, culture, or both; MDR or XDR tuberculosis confirmed by drug-susceptibility testing to first-line and second-line drugs; age older than 21 years to 65 years or younger; and absence of lesion compatible with a malignant process or ongoing tuberculosis in organs other than the lungs and pleura. In addition to the inclusion criteria, patients were excluded if they were pregnant, coinfected with HIV, or infected with hepatitis B, C, or both. The primary endpoint was safety measured by MSC-infusion related events; any tuberculosis-related event within the 6 month observation period that related to a worsening of the underlying infectious disease, measured by conversion of Mycobacterium tuberculosis culture or microscopic examination; or any adverse event defined clinically or by changes in blood haematology and biochemistry variables, measured monthly for 6 months after MSC infusion per protocol. This study is registered with the German Clinical Trials Registry, number DRKS00000763. Findings The most common (grade 1 or 2) adverse events were high cholesterol levels (14 of 30 patients), nausea (11 of 30 patients), and lymphopenia or diarrhoea (ten of 30 patients). There were no serious adverse events reported. We recorded two grade 3 events that were transitory—ie, increased plasma potassium ion concentrations in one patient and a transitory grade 3 γ-glutamyltransferase elevation in another patient. Interpretation MSCs as an adjunct therapy are safe and can now be explored further for the treatment of patients with MDR or XDR tuberculosis in combination with standard drug regimens. Adjunct treatment with MSCs needs to be evaluated in controlled phase 2 trials to assess effects on immune responses and clinical and microbiological outcomes. Funding Heart and Lung foundation, Vinnova, SIDA, Söderberg Foundation, Swedish Research Council.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
蓝星完成签到,获得积分10
3秒前
123完成签到 ,获得积分10
3秒前
guxi完成签到 ,获得积分10
4秒前
芭乐王子完成签到 ,获得积分10
5秒前
Richard完成签到 ,获得积分10
6秒前
帕尼尼同学完成签到,获得积分10
9秒前
Az完成签到 ,获得积分10
10秒前
文静凝芙完成签到,获得积分10
16秒前
烟花的应助被科研通管家采纳,获得10
17秒前
桐桐的应助被科研通管家采纳,获得10
17秒前
bkagyin的应助被科研通管家采纳,获得10
17秒前
李爱国的应助被科研通管家采纳,获得10
18秒前
wu完成签到 ,获得积分10
18秒前
NNUsusan完成签到,获得积分10
20秒前
虚心向上完成签到 ,获得积分10
21秒前
笨笨千亦完成签到 ,获得积分10
22秒前
DND完成签到,获得积分10
31秒前
33秒前
hxjtu完成签到,获得积分10
38秒前
震动的鹏飞完成签到 ,获得积分10
38秒前
gsxgg完成签到,获得积分10
43秒前
飞矢不动完成签到,获得积分10
43秒前
瓦罐完成签到 ,获得积分10
45秒前
飞儿完成签到 ,获得积分10
45秒前
win050532完成签到 ,获得积分10
48秒前
细腻的傲安完成签到,获得积分10
53秒前
清心淡如水完成签到 ,获得积分10
53秒前
风息完成签到,获得积分10
55秒前
QQ完成签到 ,获得积分10
56秒前
揽文阁完成签到 ,获得积分10
56秒前
细心又菡完成签到,获得积分20
57秒前
欢呼馒头完成签到 ,获得积分10
58秒前
斯文败类的应助被u雨采纳,获得10
1分钟前
正直从凝完成签到 ,获得积分10
1分钟前
研友_VZG7GZ的应助被季末默相依采纳,获得10
1分钟前
自觉大门完成签到,获得积分10
1分钟前
Jackcaosky完成签到 ,获得积分10
1分钟前
11qkk完成签到 ,获得积分10
1分钟前
斯文败类的应助被wangji_2017采纳,获得10
1分钟前
慕容博完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180084
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808758
捐赠科研通 7776098
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557454
邀请新用户注册赠送积分活动 2479012